Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.74 |
| ▸ | ADH1A | P07327 | 4/20 | 0.74 |
| ▸ | ADH1C | P00326 | 3/20 | 0.59 |
| ▸ | ADH7 | P40394 | 2/20 | 0.59 |
| ▸ | ADH4 | P08319 | 1/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944271 | 1.00 | ADH1B (0.74) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL12210420 | 0.87 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL19658308 | 0.86 | ADH1B (1.00) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL115609 | 0.86 | — | — | |
| SCHEMBL21997344 | 0.86 | ADH1B (1.00) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL16437032 | 0.85 | — | — | |
| Cyclohexylformamide SCHEMBL28502556 | 0.83 | ADH1B (0.77) | ADH1BADH1AADH1CADH7ADH4 | |
| Hydrochloric Acid SCHEMBL4095046 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL9205102 | 0.83 | — | — | |
| SCHEMBL21088347 | 0.80 | ADH1B (0.88) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713806-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-05-08 | — | — | EP | claimed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | claimed |
| EP-1713806-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | claimed |
| WO-2005107760-A1 | COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| WO-2005080393-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-09-01 | — | — | WO | claimed |
| WO-2022218379-A1 | SMALL-MOLECULE COMPOUND HAVING SUBSTITUTED PHENYL SPIRO[INDOLINE-3,3'-PYRROLIDINE] STRUCTURE | 中国科学院上海药物研究所 | 2022-10-20 | — | — | WO | disclosed |
| CN-109069512-A | Substituted aminopurine compounds, compositions thereof, and related methods of treatment | 西格诺药品有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-1713806-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-05-08 | — | — | EP | disclosed |
| US-7968557-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | disclosed |
| EP-1227805-B2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | disclosed |
| EP-1713806-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005107760-A1 | COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION | IRM LLC (BM) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005080393-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-09-01 | — | — | WO | disclosed |
| CN-1535272-A | Nitrogen-containing bicyclic heterocycles | ʷ | 2004-10-06 | — | — | CN | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | ADH1B 633/4885ADH1A 221/4885ADH1C 276/4885 |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ABL1, PDGFRA, PDGFRB | ADH1B 4876/4885ADH1A 4869/4885ADH1C 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.